This document is a USPTO patent application (US20260083756A1) filed by Fertin Pharma A/S on September 20, 2024. It describes a novel capsule formulation for the oral delivery of cannabinoids. The formulation includes self-emulsifying drug delivery systems (SEDDS) with at least 20% surfactants containing a polyethylene glycol (PEG) moiety, and at least 10% cannabinoids (isolated or synthetic).

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signals potential future developments in cannabinoid-based drug delivery systems. Companies involved in pharmaceutical manufacturing, particularly those working with cannabinoids or novel drug delivery technologies, should be aware of this filing as it may impact future product development and intellectual property landscapes.